- Home
- DRUG vs CTMX Comparison
DRUG vs CTMX Comparison
Compare DRUG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- CTMX
- Stock Information
- Founded
- DRUG 2019
- CTMX 2008
- Country
- DRUG United States
- CTMX United States
- Employees
- DRUG N/A
- CTMX N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- CTMX Health Care
- Exchange
- DRUG Nasdaq
- CTMX Nasdaq
- Market Cap
- DRUG 484.7M
- CTMX 544.2M
- IPO Year
- DRUG N/A
- CTMX 2015
- Fundamental
- Price
- DRUG $69.38
- CTMX $3.65
- Analyst Decision
- DRUG Strong Buy
- CTMX Strong Buy
- Analyst Count
- DRUG 9
- CTMX 5
- Target Price
- DRUG $81.67
- CTMX $5.80
- AVG Volume (30 Days)
- DRUG 108.7K
- CTMX 4.6M
- Earning Date
- DRUG 08-11-2025
- CTMX 11-06-2025
- Dividend Yield
- DRUG N/A
- CTMX N/A
- EPS Growth
- DRUG N/A
- CTMX 263.20
- EPS
- DRUG N/A
- CTMX 0.49
- Revenue
- DRUG N/A
- CTMX $141,100,000.00
- Revenue This Year
- DRUG N/A
- CTMX N/A
- Revenue Next Year
- DRUG N/A
- CTMX N/A
- P/E Ratio
- DRUG N/A
- CTMX $7.39
- Revenue Growth
- DRUG N/A
- CTMX 18.01
- 52 Week Low
- DRUG $23.18
- CTMX $0.40
- 52 Week High
- DRUG $70.23
- CTMX $3.91
- Technical
- Relative Strength Index (RSI)
- DRUG 68.34
- CTMX 69.11
- Support Level
- DRUG $62.21
- CTMX $3.17
- Resistance Level
- DRUG $70.23
- CTMX $3.48
- Average True Range (ATR)
- DRUG 6.00
- CTMX 0.24
- MACD
- DRUG 0.52
- CTMX 0.00
- Stochastic Oscillator
- DRUG 96.01
- CTMX 69.42
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.